KR102641731B1 - 에볼라 바이러스 당단백질에 대한 인간 항체 - Google Patents

에볼라 바이러스 당단백질에 대한 인간 항체 Download PDF

Info

Publication number
KR102641731B1
KR102641731B1 KR1020177021579A KR20177021579A KR102641731B1 KR 102641731 B1 KR102641731 B1 KR 102641731B1 KR 1020177021579 A KR1020177021579 A KR 1020177021579A KR 20177021579 A KR20177021579 A KR 20177021579A KR 102641731 B1 KR102641731 B1 KR 102641731B1
Authority
KR
South Korea
Prior art keywords
antibody
amino acid
ebov
seq
ebola virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177021579A
Other languages
English (en)
Korean (ko)
Other versions
KR20170102328A (ko
Inventor
크리스토스 키라트소우스
윌리암 올슨
피터 메이슨
니일 스탈
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55300806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102641731(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Publication of KR20170102328A publication Critical patent/KR20170102328A/ko
Application granted granted Critical
Publication of KR102641731B1 publication Critical patent/KR102641731B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020177021579A 2015-01-26 2016-01-25 에볼라 바이러스 당단백질에 대한 인간 항체 Active KR102641731B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562107581P 2015-01-26 2015-01-26
US62/107,581 2015-01-26
US201562161356P 2015-05-14 2015-05-14
US62/161,356 2015-05-14
US201562245703P 2015-10-23 2015-10-23
US62/245,703 2015-10-23
PCT/US2016/014720 WO2016123019A1 (en) 2015-01-26 2016-01-25 Human antibodies to ebola virus glycoprotein

Publications (2)

Publication Number Publication Date
KR20170102328A KR20170102328A (ko) 2017-09-08
KR102641731B1 true KR102641731B1 (ko) 2024-02-29

Family

ID=55300806

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177021579A Active KR102641731B1 (ko) 2015-01-26 2016-01-25 에볼라 바이러스 당단백질에 대한 인간 항체

Country Status (21)

Country Link
US (6) US9771414B2 (enExample)
EP (2) EP3250591B1 (enExample)
JP (4) JP6829199B2 (enExample)
KR (1) KR102641731B1 (enExample)
CN (2) CN113354732B (enExample)
AU (2) AU2016211783B2 (enExample)
BR (1) BR112017015845A2 (enExample)
CA (1) CA2974899A1 (enExample)
CL (3) CL2017001920A1 (enExample)
CO (1) CO2017007619A2 (enExample)
EA (1) EA038993B1 (enExample)
IL (1) IL253358B (enExample)
MA (1) MA41421A (enExample)
MX (2) MX392533B (enExample)
MY (4) MY189452A (enExample)
PH (1) PH12017501277B1 (enExample)
PT (1) PT3250591T (enExample)
SG (2) SG10202007835QA (enExample)
TW (1) TWI710573B (enExample)
UY (1) UY36538A (enExample)
WO (1) WO2016123019A1 (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
JP2014527799A (ja) 2011-08-26 2014-10-23 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
JP2019510481A (ja) 2016-02-19 2019-04-18 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン開発のための改善されたｂ型インフルエンザウイルス複製
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
WO2018017964A2 (en) 2016-07-21 2018-01-25 Emory University Ebola virus antibodies and binding agents derived therefrom
US11020686B2 (en) 2016-08-16 2021-06-01 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
BR112019006689A2 (pt) 2016-10-25 2019-06-25 Regeneron Pharma métodos e sistemas para análise de dados de cromatografia
CN108570106B (zh) * 2017-03-10 2021-07-16 北京天广实生物技术股份有限公司 抗埃博拉病毒单克隆抗体、其制备方法及用途
AU2018298039B2 (en) 2017-07-06 2023-02-02 Regeneron Pharmaceuticals, Inc. Cell culture process for making a glycoprotein
US12162925B2 (en) * 2017-09-15 2024-12-10 The Wistar Institute Of Anatomy And Biology DNA-encoded monoclonal antibodies targeting the Ebolavirus glycoprotein
US12042538B2 (en) 2017-09-19 2024-07-23 Regeneron Pharmaceuticals, Inc. Methods of reducing particle formation and compositions formed thereby
EP3700562A1 (en) 2017-10-25 2020-09-02 Wisconsin Alumni Research Foundation (WARF) Recombinant influenza viruses with stabilized ha for replication in eggs
SG11202004380QA (en) 2017-12-22 2020-06-29 Regeneron Pharma System and method for characterizing drug product impurities
RU2686630C1 (ru) * 2017-12-22 2019-04-29 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Штаммы гибридных клеток животных Mus. Musculus - продуценты моноклональных антител к белку GP вируса Эбола (subtype Zaire) и моноклональные антитела к белку GP вируса Эбола (subtype Zaire)
WO2019136029A1 (en) * 2018-01-02 2019-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
CN111655722A (zh) 2018-01-31 2020-09-11 瑞泽恩制药公司 用于表征药物产品杂质的系统和方法
US20210047388A1 (en) * 2018-01-31 2021-02-18 The Wistar Institute Of Anatomy And Biology Nucleic acid antibody constructs for use against ebola virus
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
BR112020013426A2 (pt) 2018-02-28 2020-12-01 Regeneron Pharmaceuticals, Inc. métodos para identificação de um vírus em uma amostra e para detecção de ácidos nucleicos virais em uma amostra de cultura de células
CN108373500A (zh) * 2018-03-12 2018-08-07 中国科学院微生物研究所 一种热稳定性埃博拉治疗性抗体的制备及应用
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
EA202092203A1 (ru) 2018-03-19 2020-12-07 Ридженерон Фармасьютикалз, Инк. Способы анализа и реагенты для микрочипового капиллярного электрофореза
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
CN112088166A (zh) * 2018-03-26 2020-12-15 瑞泽恩制药公司 抗PfRH5抗体和其抗原结合片段
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
US11939370B2 (en) * 2018-07-12 2024-03-26 Vanderbilt University Pan-ebola virus neutralizing human antibodies and methods of use therefor
JP7783047B2 (ja) 2018-08-07 2025-12-09 ウィスコンシン アルムニ リサーチ ファンデイション 組換えの生物学的に封じ込められたフィロウイルスワクチン
EP3840780A1 (en) 2018-08-20 2021-06-30 Wisconsin Alumni Research Foundation Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein
EA202092684A1 (ru) 2018-08-27 2021-03-11 Ридженерон Фармасьютикалз, Инк. Применение рамановской спектроскопии для последующей очистки
TWI866924B (zh) 2018-08-30 2024-12-21 美商再生元醫藥公司 用於將蛋白質複合物定特徵之方法
CN111138528B (zh) * 2018-11-06 2021-07-30 中国人民解放军军事科学院军事医学研究院 特异性结合于埃博拉病毒糖蛋白聚糖帽的单克隆抗体5a8
CN111138531B (zh) * 2018-11-06 2021-07-30 中国人民解放军军事科学院军事医学研究院 特异结合于ebov的gp1亚基的单克隆抗体8f9及应用
CN111138527B (zh) * 2018-11-06 2021-07-30 中国人民解放军军事科学院军事医学研究院 抗埃博拉病毒糖蛋白gp1亚基的单克隆抗体4f1及应用
CN111138526B (zh) * 2018-11-06 2021-07-30 中国人民解放军军事科学院军事医学研究院 一种抗埃博拉病毒糖蛋白gp2亚基的单克隆抗体2g1及应用
CN117110492A (zh) 2019-01-16 2023-11-24 瑞泽恩制药公司 鉴别蛋白质中的游离巯基的方法
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
SG11202110911RA (en) 2019-05-13 2021-10-28 Regeneron Pharma Improved competitive ligand binding assays
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
JP6761889B1 (ja) * 2019-11-11 2020-09-30 株式会社Ｇｓｐエンタープライズ 抗ヒトＣｒｉｐｔｏ−１抗体
IL293112A (en) 2019-11-25 2022-07-01 Regeneron Pharma Sustained release formulations using non-aqueous emulsions
GB201917480D0 (en) * 2019-11-29 2020-01-15 Univ Oxford Innovation Ltd Antibodies
BR112022014212B1 (pt) 2020-01-21 2024-01-23 Regeneron Pharmaceuticals, Inc Métodos de análise de uma amostra incluindo uma proteína de interesse
KR20220131923A (ko) * 2020-01-24 2022-09-29 리제너론 파마슈티칼스 인코포레이티드 안정한 항체 제형
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US11168128B2 (en) 2020-02-26 2021-11-09 Vir Biotechnology, Inc. Antibodies against SARS-CoV-2 and methods of using the same
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
BR112023000489A2 (pt) * 2020-07-13 2023-03-28 Regeneron Pharma Análogos de camptotecina conjugados a um resíduo de glutamina em uma proteína, e seu uso
KR20230058094A (ko) 2020-08-31 2023-05-02 리제너론 파아마슈티컬스, 인크. 세포 배양 성능을 개선하고 아스파라긴 서열 변이체를 완화하기 위한 아스파라긴 공급 전략
WO2022074630A1 (en) * 2020-10-09 2022-04-14 Auxilla Pharmaceuticals And Research Llp Liquid oral suspension of favipiravir
WO2022115588A1 (en) 2020-11-25 2022-06-02 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
US12350374B2 (en) 2020-12-17 2025-07-08 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
EP4274608A4 (en) * 2021-01-05 2025-07-09 Immunome Inc ANTIBODY COCKTAIL AGAINST SARS-CoV-2 SPIKE PROTEIN
JP2024503408A (ja) 2021-01-20 2024-01-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 細胞培養におけるタンパク質力価の改善方法
JP2024512299A (ja) 2021-03-03 2024-03-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タンパク質の粘度を定量及び変更するためのシステム及び方法
CA3220848A1 (en) 2021-06-01 2022-12-08 Timothy Riehlman Microchip capillary electrophoresis assays and reagents
US20230077710A1 (en) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
CN118139881A (zh) 2021-09-20 2024-06-04 瑞泽恩制药公司 控制抗体异质性的方法
TW202323817A (zh) 2021-10-07 2023-06-16 美商再生元醫藥公司 Ｐｈ建模及控制之系統及方法
IL311248A (en) 2021-10-07 2024-05-01 Regeneron Pharma PH meter calibration and repair
TW202330104A (zh) 2021-10-26 2023-08-01 美商再生元醫藥公司 用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法
JP2025503700A (ja) 2022-01-14 2025-02-04 レジェネロン ファーマシューティカルズ， インコーポレイテッド ベルカリンａ誘導体及びその抗体薬物複合体
WO2024158880A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
EP4655595A1 (en) 2023-01-25 2025-12-03 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
WO2024163708A1 (en) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
US20240280551A1 (en) 2023-02-22 2024-08-22 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
AU2024265540A1 (en) 2023-05-01 2025-10-30 Regeneron Pharmaceuticals, Inc. Multidose antibody drug products using phenol or benzyl alcohol
TW202532098A (zh) 2023-09-29 2025-08-16 美商再生元醫藥公司 使用控制成核之冷凍乾燥
WO2025085594A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
TW202535934A (zh) 2023-11-02 2025-09-16 美商再生元醫藥公司 利用應力來降低脂酶活性的方法
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
CN120623329A (zh) * 2025-01-15 2025-09-12 中国人民解放军军事科学院军事医学研究院 抗埃博拉病毒vp40蛋白的纳米抗体3e07及在病毒检测中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630144B1 (en) 1999-08-30 2003-10-07 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies to Ebola glycoprotein
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6875433B2 (en) 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
CA2712605C (en) 2008-02-01 2017-02-07 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Monoclonal antibodies for ebola and marburg viruses
EP3351628B1 (en) 2008-10-24 2023-07-26 The Government of The United States of America as represented by The Secretary, Department of Health and Human Services Human ebola virus species and compositions and methods thereof
ES2527173T3 (es) 2009-06-02 2015-01-21 Regeneron Pharmaceuticals, Inc. Células de fucosilación deficiente
ES2865648T3 (es) 2009-06-26 2021-10-15 Regeneron Pharma Anticuerpos biespecíficos fácilmente aislados con formato de inmunoglobulina nativa
US9097713B2 (en) 2009-09-02 2015-08-04 The United States Of America As Represented By The Secretary Of The Army On Behalf Of Usamrmc Monoclonal antibodies against glycoprotein of Ebola sudan boniface virus
WO2016028503A1 (en) 2014-08-20 2016-02-25 Albert Einstein College Of Medicine, Inc. Therapy for filovirus infection
US9346875B2 (en) 2013-06-03 2016-05-24 Albert Einstein College Of Medicine, Inc. Therapy for filovirus infection
EP3107582A4 (en) 2014-02-19 2018-02-14 Emergent BioSolutions Canada Inc. Ebola monoclonal antibodies
CN103864904B (zh) * 2014-03-04 2016-01-20 中国人民解放军军事医学科学院生物工程研究所 基于埃博拉病毒包膜蛋白的抗原片段、截短体及应用
WO2015200522A2 (en) 2014-06-25 2015-12-30 Integrated Biotherapeutics, Inc. Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species
CA2963470A1 (en) 2014-10-03 2016-04-07 Massachusetts Institute Of Technology Antibodies that bind ebola glycoprotein and uses thereof
WO2016061504A2 (en) 2014-10-17 2016-04-21 The University Of Chicago Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Clinical Immunology (2011) 141, 218-227

Also Published As

Publication number Publication date
CN107667115B (zh) 2021-12-21
AU2016211783B2 (en) 2021-07-22
NZ733620A (en) 2024-09-27
TWI710573B (zh) 2020-11-21
EP3250591B1 (en) 2025-11-12
US10081670B2 (en) 2018-09-25
JP2018506966A (ja) 2018-03-15
US9771414B2 (en) 2017-09-26
JP7672200B2 (ja) 2025-05-07
US20190048066A1 (en) 2019-02-14
EP3250591A1 (en) 2017-12-06
US20210024617A1 (en) 2021-01-28
UY36538A (es) 2016-08-31
EP4653051A2 (en) 2025-11-26
CL2020000498A1 (es) 2020-11-13
PH12017501277A1 (en) 2018-01-29
JP2023065648A (ja) 2023-05-12
PT3250591T (pt) 2025-11-19
SG10202007835QA (en) 2020-09-29
EA038993B1 (ru) 2021-11-18
SG11201705681YA (en) 2017-08-30
US20200148751A1 (en) 2020-05-14
AU2016211783A1 (en) 2017-07-27
US11530255B2 (en) 2022-12-20
IL253358A0 (en) 2017-09-28
US20160215040A1 (en) 2016-07-28
CN113354732A (zh) 2021-09-07
EA201791675A1 (ru) 2017-12-29
BR112017015845A2 (pt) 2018-03-27
TW201639883A (zh) 2016-11-16
MX2021015687A (es) 2022-02-03
JP2020120683A (ja) 2020-08-13
IL253358B (en) 2021-07-29
CO2017007619A2 (es) 2017-10-20
US12152067B2 (en) 2024-11-26
WO2016123019A1 (en) 2016-08-04
MA41421A (fr) 2017-12-05
CN113354732B (zh) 2024-07-09
PH12017501277B1 (en) 2022-07-20
CL2017001920A1 (es) 2018-03-02
CN107667115A (zh) 2018-02-06
MY208081A (en) 2025-04-14
US10829544B2 (en) 2020-11-10
AU2021202839A1 (en) 2021-06-03
MY180045A (en) 2020-11-20
JP6829199B2 (ja) 2021-02-10
US20240327501A1 (en) 2024-10-03
MX392533B (es) 2025-03-24
JP2025065427A (ja) 2025-04-17
KR20170102328A (ko) 2017-09-08
US10501526B2 (en) 2019-12-10
MY189452A (en) 2022-02-14
CA2974899A1 (en) 2016-08-04
CL2022003763A1 (es) 2023-06-30
MX2017009716A (es) 2018-04-24
MY196224A (en) 2023-03-23
US20170355751A1 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
KR102641731B1 (ko) 에볼라 바이러스 당단백질에 대한 인간 항체
JP7500812B2 (ja) 中東呼吸器症候群－コロナウイルススパイクタンパク質に対するヒト抗体
KR102729973B1 (ko) 인플루엔자 헤마글루티닌에 대한 인간 항체
KR20190030206A (ko) 항-지카 바이러스 항체 및 사용 방법
CN111670195B (zh) 针对流感血凝素的人抗体
KR20230051683A (ko) 액티빈 a 길항제를 사용한 심장 기능 장애 및 covid-19의 예방 및 치료 방법
OA18324A (en) Human antibodies to Ebola virus glycoprotein.
EA048493B1 (ru) Применение фармацевтических композиций человеческих антител к гликопротеину вируса эбола

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000